(HOLX) Hologic - Ratings and Ratios
Diagnostics, Medical Imaging, Surgical Products, Womens Health
HOLX EPS (Earnings per Share)
HOLX Revenue
Description: HOLX Hologic
Hologic Inc. is a leading player in the healthcare equipment industry, specializing in womens health through early detection and treatment. The company operates through four main segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, offering a diverse range of products and solutions.
The Diagnostics segment is a key contributor, with a portfolio of molecular diagnostic assays, including Aptima and Panther Fusion, which detect infectious microorganisms and viruses, such as SARS-CoV-2. The Breast Health segment offers a comprehensive range of breast cancer care solutions, including 3D digital mammography systems, image analytics software, and minimally invasive breast biopsy guidance systems.
From a financial perspective, Hologic has demonstrated a strong track record of revenue growth, driven by its innovative product portfolio and strategic acquisitions. Key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating margin are crucial in evaluating the companys financial health. With a market capitalization of $14.6 billion, Hologics financials indicate a stable and profitable business model.
To further analyze Hologics performance, we can examine additional KPIs, such as return on equity (ROE) of 11.44%, indicating a relatively stable return on shareholder investment. The companys forward price-to-earnings (P/E) ratio of 14.53 suggests a moderate valuation compared to its expected earnings growth. Furthermore, Hologics dividend yield and payout ratio can provide insights into its shareholder return strategy.
Overall, Hologics diversified product portfolio, strong financials, and commitment to innovation position the company for continued growth and success in the healthcare equipment industry.
HOLX Stock Overview
| Market Cap in USD | 14,849m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1990-06-21 |
HOLX Stock Ratings
| Growth Rating | -29.2% |
| Fundamental | 66.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -35.1% |
| Analyst Rating | 3.45 of 5 |
HOLX Dividends
Currently no dividends paidHOLX Growth Ratios
| Growth Correlation 3m | 54.2% |
| Growth Correlation 12m | -63.9% |
| Growth Correlation 5y | -4.9% |
| CAGR 5y | -1.44% |
| CAGR/Max DD 3y | -0.04 |
| CAGR/Mean DD 3y | -0.10 |
| Sharpe Ratio 12m | -0.75 |
| Alpha | -40.69 |
| Beta | 0.984 |
| Volatility | 21.65% |
| Current Volume | 1276.2k |
| Average Volume 20d | 1276.2k |
| Stop Loss | 61.8 (-3.1%) |
| Signal | -1.48 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (557.1m TTM) > 0 and > 6% of Revenue (6% = 242.3m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -0.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 60.88% (prev 75.10%; Δ -14.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.07b > Net Income 557.1m (YES >=105%, WARN >=100%) |
| Net Debt (787.3m) to EBITDA (1.01b) ratio: 0.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (225.5m) change vs 12m ago -4.65% (target <= -2.0% for YES) |
| Gross Margin 51.80% (prev 55.14%; Δ -3.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.65% (prev 44.85%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.15 (EBITDA TTM 1.01b / Interest Expense TTM 120.4m) >= 6 (WARN >= 3) |
Altman Z'' 4.42
| (A) 0.28 = (Total Current Assets 3.42b - Total Current Liabilities 962.5m) / Total Assets 8.81b |
| (B) 0.37 = Retained Earnings (Balance) 3.22b / Total Assets 8.81b |
| (C) 0.08 = EBIT TTM 740.2m / Avg Total Assets 8.85b |
| (D) 0.79 = Book Value of Equity 3.14b / Total Liabilities 3.96b |
| Total Rating: 4.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.94
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 6.32% = 3.16 |
| 3. FCF Margin 24.22% = 6.06 |
| 4. Debt/Equity 0.52 = 2.37 |
| 5. Debt/Ebitda 2.49 = -0.95 |
| 6. ROIC - WACC 0.78% = 0.97 |
| 7. RoE 11.51% = 0.96 |
| 8. Rev. Trend 14.00% = 0.70 |
| 9. Rev. CAGR 2.63% = 0.33 |
| 10. EPS Trend 51.83% = 1.30 |
| 11. EPS CAGR 10.53% = 1.05 |
What is the price of HOLX shares?
Over the past week, the price has changed by -4.12%, over one month by -5.91%, over three months by -2.12% and over the past year by -22.85%.
Is Hologic a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HOLX is around 55.57 USD . This means that HOLX is currently overvalued and has a potential downside of -12.9%.
Is HOLX a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 14
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HOLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 73.9 | 15.8% |
| Analysts Target Price | 73.9 | 15.8% |
| ValueRay Target Price | 61.9 | -3% |
Last update: 2025-09-09 04:39
HOLX Fundamental Data Overview
CCE Cash And Equivalents = 1.88b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 27.7012
P/E Forward = 14.6413
P/S = 3.6764
P/B = 3.0663
P/EG = 1.4714
Beta = 0.572
Revenue TTM = 4.04b USD
EBIT TTM = 740.2m USD
EBITDA TTM = 1.01b USD
Long Term Debt = 2.51b USD (from longTermDebt, last quarter)
Short Term Debt = 3.40m USD (from shortTermDebt, last quarter)
Debt = 2.51b USD (Calculated: Short Term 3.40m + Long Term 2.51b)
Net Debt = 787.3m USD (from netDebt column, last quarter)
Enterprise Value = 15.48b USD (14.85b + Debt 2.51b - CCE 1.88b)
Interest Coverage Ratio = 6.15 (Ebit TTM 740.2m / Interest Expense TTM 120.4m)
FCF Yield = 6.32% (FCF TTM 978.2m / Enterprise Value 15.48b)
FCF Margin = 24.22% (FCF TTM 978.2m / Revenue TTM 4.04b)
Net Margin = 13.79% (Net Income TTM 557.1m / Revenue TTM 4.04b)
Gross Margin = 51.80% ((Revenue TTM 4.04b - Cost of Revenue TTM 1.95b) / Revenue TTM)
Tobins Q-Ratio = 4.93 (Enterprise Value 15.48b / Book Value Of Equity 3.14b)
Interest Expense / Debt = 1.15% (Interest Expense 28.9m / Debt 2.51b)
Taxrate = 8.74% (75.6m / 865.1m)
NOPAT = 675.5m (EBIT 740.2m * (1 - 8.74%))
Current Ratio = 3.55 (Total Current Assets 3.42b / Total Current Liabilities 962.5m)
Debt / Equity = 0.52 (Debt 2.51b / last Quarter total Stockholder Equity 4.84b)
Debt / EBITDA = 2.49 (Net Debt 787.3m / EBITDA 1.01b)
Debt / FCF = 2.57 (Debt 2.51b / FCF TTM 978.2m)
Total Stockholder Equity = 4.84b (last 4 quarters mean)
RoA = 6.33% (Net Income 557.1m, Total Assets 8.81b )
RoE = 11.51% (Net Income TTM 557.1m / Total Stockholder Equity 4.84b)
RoCE = 10.07% (Ebit 740.2m / (Equity 4.84b + L.T.Debt 2.51b))
RoIC = 9.17% (NOPAT 675.5m / Invested Capital 7.36b)
WACC = 8.40% (E(14.85b)/V(17.36b) * Re(9.64%)) + (D(2.51b)/V(17.36b) * Rd(1.15%) * (1-Tc(0.09)))
Shares Correlation 3-Years: -93.94 | Cagr: -1.03%
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.88% ; FCFE base≈992.7m ; Y1≈950.1m ; Y5≈923.2m
Fair Price DCF = 56.54 (DCF Value 12.58b / Shares Outstanding 222.4m; 5y FCF grow -5.69% → 3.0% )
EPS Correlation: 51.83 | EPS CAGR: 10.53% | SUE: 1.53 | # QB: True
Revenue Correlation: 14.00 | Revenue CAGR: 2.63%
Additional Sources for HOLX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle